行情

NVO

NVO

诺和诺德
NYSE

实时行情|Nasdaq Last Sale

54.50
+0.46
+0.85%
交易中 14:35 11/22 EST
开盘
54.97
昨收
54.04
最高
54.99
最低
54.29
成交量
120.47万
成交额
--
52周最高
58.01
52周最低
43.60
市值
1,277.24亿
市盈率(TTM)
22.96
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVO 新闻

  • Why Eli Lilly Can't Match Novo Nordisk
  • Seeking Alpha - Article.16小时前
  • Novo Nordisk Continues NASH Pipeline Push With Latest Product Bolt On
  • Seeking Alpha - Article.1天前
  • Sanofi's Positive Diabetes Study Offers A New Treatment Alternative For Patients
  • Seeking Alpha - Article.1天前
  • Launch of new generic drugs in U.S. still lags - WSJ
  • Seeking Alpha - Article.2天前

更多

所属板块

制药
+0.53%
制药与医学研究
+0.77%

热门股票

名称
价格
涨跌幅

NVO 简况

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
展开

Webull提供Novo Nordisk A/S (ADR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。